Monocyte Chemoattractant Protein-1 in Psoriatic Arthritis Patients

Not yet recruiting

• Conditions: Psoriatic Arthritis

• Registration Number: NCT05637905
• Lead Sponsor: Assiut University

Brief Summary

1. Evaluate serum levels of (MCP-1) in PsA with or without cardiovascular affaction .

2. Detect subclinical cardiovascular affaction in patients with PsA for early diagnosis and management .

Detailed Description

Psoriatic arthritis (PSA) is an autoimmune disease arising from the interply between proinflamatory cytokines

\[1\]and external stimuli in genetically predisposed individuals.\[2\]

* The disease is chronic and affects the peripheral joints and may include axial skeleton with or without extrarticular manifestations.\[3\]

* Abnormal activation of the innate and adaptive immune systems contributes to chronic disease processes in both psoriasis and PSA .\[4\] The skin and the joints exhibit a prominent lymphocytic infiltrate consisting of activated CD4+ and CD8+ T cells as well as an increase in neutrophil infiltration\[5\].

Patients with PsA have a higher risk of developing a cardiovascular(CV) events than the general population. This could be attributed to the higher prevalence of traditional cardiovascular risk factors and to the disease characteristics such as systemic inflammation. \[6\] These patients may show asymptomatic cardiomyopathy even in the absence of traditional risk factors \[7\].Cardiac dysfunction is associated with a poor prognosis, increased mortality, and affact socioecenomic function of patients therefore, the diagnosis of the cardiac dysfunction in the asymptomatic phase of the disease \[8\] is important for the timely introduction of therapy \[9\].Monocyte chemotactic protien1(MCP-1) is a member of chemotactic chemokines(CC) which are secreted by immune effector cells and dysfunctional endothelium \[10\].

* The pivotal function of MCP-1 is to attract monocyte in the arterial wall through increased expression of adhesion molecules on their surface that interacts with endothelium\[11\].

* MCP-1 induce maturation of monocyte in the arterial wall ,which then become specialized macrophage in early atheroma and produce tissue factors supporting coagulation and proinflammatory cytokines such as IL-1 and IL-6. It affects the functions of the surrounding immune effector cells in locally thickened intima.\[12\]

* During active disease in psoriatic skin lesions and synovial tissue, activated monocytes represent the major source of proinflammatory mediators, including the chemokine MCP-1 \[13\]. MCP-1 is thought to be involved in the pathogenesis of oedema and bone erosion in patients with PsA \[14\].

Study Timeline

• Status Verified: 2022-11
• Study First Submitted: 2022-11-25
• Study First Submitted QC: 2022-11-25
• Last Update Submitted: 2022-11-25
• Study First Posted: 2022-12-06
• Last Update Posted: 2022-12-06
• Study Start: 2023-01
• Primary Completion: 2023-03
• Study Completion: 2025-06

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

• PsA patients (age ≥ 18years) who fulfilled the CASPAR classification criteria[15]for psoriatic arthritis

Exclusion Criteria

• PsA patients with

  1. infection.
  2. bone marrow disorders.
  3. other autoimmune diseases.
  4. diabetes.
  5. hypertention .
  6. hyperlipidemia.
  7. liver diseases.
  8. renal diseases.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
MCP-1	two month	:Evaluate serum levels of monocyte chemoattractant protein-1(MCP-1) in relation to echocardiographic changes in patient with psoriatic arthritis.

Secondary Outcome Measures

Name	Time	Method
Echocardiography	two month	b.Detect subclinical cardiovascular affaction in patient with psoriatic arthritis.